Description

Long Term Management of Psychosis
Chronically psychotic patients in the maintenance phase of treatment are frequently medication non-adherent and have inadequate community supports; relapse is common.  This learning program will teach participants to identify the multiple barriers to successful maintenance treatment and recovery.  Participants will also learn specific strategies to address these obstacles and maximize the long-term health and stability of chronically psychotic patients.

Optimal Care of Depression
Major Depressive Disorder (MDD) is a largely chronic and highly debilitating illness affecting approximately twelve to twenty percent of the world’s population, and ranking within the top ten causes of death worldwide. In addition to overwhelming personal and family financial burdens, the overall labor cost of major depressive disorder in the United States is about $30-44 billion a year, a consequence of work absence and reduced performance while at work. Therefore, providing educational interventions aimed at integrating the essential elements that comprise optimal management of depression is of the utmost importance.

Learning Objectives

Long Term Management of Psychosis
1. Identify barriers to treatment adherence in chronically psychotic patients, and demonstrate the ability to effectively assess and promote treatment adherence during office visits.
2. Perform an appropriate baseline assessment of patients to identify risk factors for developing metabolic abnormalities, institute a periodic monitoring regimen to assess patients for antipsychotic-induced metabolic side effects, and counsel patients on methods to prevent or minimize metabolic problems.
3. Effectively promote psychosocial rehabilitation of chronically psychotic patients by incorporating skills training, vocational support, substance abuse treatment, family psychoeducation, and targeted psychotherapeutic techniques in an outpatient treatment plan.

Optimal Care of Depression
1. Examine the cultural barriers that hinder the adequate delivery and use of mental health care services for the treatment of depression among minority populations incorporating methods of early detection and prevention of unipolar depression.
2. Review the indications and efficacy of available pharmacologic and psychotherapeutic treatment options for depression
3. Describe methods to determine the treatment strategies that are best suited for specific patient populations.
4. Explain the factors that constitute barriers to full functional recovery from depression including medication side effect management, cognitive impairment and optimal multimodal therapy strategies.

Agenda

Saturday, June 12, 2010

7:30AM – 8:00AM	Registration and Continental Breakfast
8:00AM – 8:10AM	Welcome and Opening Remarks/Pre-Activity Questions
8:10AM – 9:00AM	Maximizing Adherence to Treatment Oliver Freudenreich, MD
9:00AM – 9:50AM	Identifying and Managing Antipsychotic-Induced Metabolic Effects David C. Henderson, MD
9:50AM – 10:00AM	Break
10:00AM – 10:50AM	Assertive Psychosocial Rehabilitation and Community Re-Integration Corinne Cather, PhD
10:50AM – 11:40AM	Case Reviews Moderator- John Fromson, MD The Non-Adherent Patient; Evaluating and Treating a Patient with Metabolic Side-Effects; and Assessing and Providing Post-Hospitalization Community Support
11:40AM – 12:00PM	Panel Discussion
12:00PM – 12:30PM	Lunch
12:30PM – 12:40PM	Welcome and Opening Remarks
12:40PM – 1:30PM	Optimizing Pharmacotherapy in Major Depressive Disorder Jonathan Alpert, MD, PhD
1:30PM – 2:15PM	Script Concordance Questions Robert J. Birnbaum, MD, PhD
2:15PM – 3:00PM	Integrating Psychotherapy and Psychopharmacology: Encompasing Cultural Considerations Albert Yeung, MD, ScD
3:00PM – 3:45PM	Barriers to Functional Recovery David Mischoulon, MD, PhD
3:45PM – 4:30PM	Post-Activity Questions and Panel Discussion All Faculty

Faculty

Oliver Freudenreich, MD
Director, First Episode and Early Psychosis Program
Massachusetts General Hospital
Assistant Professor of Psychiatry
Harvard Medical School

David C. Henderson, MD
Director, Schizophrenia Diabetes and Weight Reduction Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School

Corrine Cather, PhD
Psychologist, Schizophrenia Program
Massachusetts General Hospital
Instructor in Psychiatry
Harvard Medical School

Jonathan E. Alpert, MD, PhD
Clinical Director, Department of Psychiatry, Associate Director, Depression Clinical and Research Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Director, Medical Student Education in Psychiatry Harvard Medical School

David Mischoulon, MD, PhD
Director, Alternative Remedy Studies, The Depression Clinical and Research Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School

Albert Yeung, MD, ScD
Assistant Psychiatrist, Massachusetts General Hospital; Assistant Professor of Psychiatry, Harvard Medical School

General Information

Long Term Management of Psychosis
Chronically psychotic patients in the maintenance phase of treatment are frequently medication non-adherent and have inadequate community supports; relapse is common.  This learning program will teach participants to identify the multiple barriers to successful maintenance treatment and recovery.  Participants will also learn specific strategies to address these obstacles and maximize the long-term health and stability of chronically psychotic patients.

Optimal Care of Depression
Major Depressive Disorder (MDD) is a largely chronic and highly debilitating illness affecting approximately twelve to twenty percent of the world’s population, and ranking within the top ten causes of death worldwide. In addition to overwhelming personal and family financial burdens, the overall labor cost of major depressive disorder in the United States is about $30-44 billion a year, a consequence of work absence and reduced performance while at work. Therefore, providing educational interventions aimed at integrating the essential elements that comprise optimal management of depression is of the utmost importance.

Accreditation

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital, Massachusetts General Hospital Academy and Reed Medical Education. McLean Hospital is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation
McLean Hospital designates this continuing medical educational activity for a maximum of 7.5 AMA PRA Category 1 Credits(TM). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Supporters

Our evidence-based curriculum is supported by educational grants.

The morning program on Psychosis is supported by:
Janssen & Pfizer

The afternoon program on Depression is supported by:
AstraZeneca, Bristol-Myers Squibb, and Lilly

• 
  
• 
  
• 
  
• 
  
•